#image_title
The ongoing shortage of glucagon-like peptide 1 receptor (GLP-1) agonists such as semaglutide (marketed as Wegovy and Ozempic) is a “major public health concern” that is unlikely to be resolved in 2024, the European Medicines Agency has warned.
Speaking at a briefing on 26 June on how the EU is tackling these shortages, the EMA’s executive director, Emer Cooke, said, “Despite our collective efforts the shortages continue and there are no instant solutions, and we don’t expect them to be resolved this year.”
As a result the EMA has issued recommendations for industry and healthcare professionals to try to reduce the negative effects of shortages on people with type 2 diabetes and obesity.1 These includes …
A former cryptocurrency company plans to launch a reality television series that will follow its…
Credit: Unsplash/CC0 Public Domain It is time to use more precise terminology and change the…
Portugal’s Cristiano Ronaldo is seen after the win against Slovenia during a round of sixteen…
Savannah Chrisley is looking ahead after mom Julie Chrisley's prison sentence was overturned. In fact,…
Tactical voting has hit the headlines once again in the build-up to the general election.According…
Department of Social Welfare and Development (DSWD) Undersecretary for Inclusive – Sustainable Peace and Special…
This website uses cookies.